New Vaccine Design Based on Defective Genomes That Combines Features of Attenuated and Inactivated Vaccines by Rodríguez-Calvo, Teresa et al.
New Vaccine Design Based on Defective Genomes That
Combines Features of Attenuated and Inactivated
Vaccines
Teresa Rodrı ´guez-Calvo
1., Samuel Ojosnegros
2., Marta Sanz-Ramos
1,2, Juan Garcı ´a-Arriaza
2¤, Cristina
Escarmı ´s
2, Esteban Domingo
2,3, Noemı ´ Sevilla
1*
1Centro de Investigacio ´n en Sanidad Animal, Instituto Nacional de Investigacio ´n y Tecnologı ´a Agraria y Alimentaria (INIA), Madrid, Spain, 2Centro de Biologı ´a Molecular
Severo Ochoa (CSIC-UAM), Madrid, Spain, 3Centro de Investigacio ´n Biome ´dica en Red de Enfermedades Hepa ´ticas y Digestivas (CIBERehd), Barcelona, Spain
Abstract
Background: New vaccine designs are needed to control diseases associated with antigenically variable RNA viruses. Foot-
and-mouth disease (FMD) is a highly contagious disease of livestock that inflicts severe economic losses. Although the
current whole-virus chemically inactivated vaccine has proven effective, it has led to new outbreaks of FMD because of
incomplete inactivation of the virus or the escape of infectious virus from vaccine production premises. We have previously
shown that serial passages of FMD virus (FMDV) C-S8c1 at high multiplicity of infection in cell culture resulted in virus
populations consisting of defective genomes that are infectious by complementation (termed C-S8p260).
Principal Finding: Here we evaluate the immunogenicity of C-S8p260, first in a mouse model system to establish a proof of
principle, and second, in swine, the natural host of FMDV C-S8c1. Mice were completely protected against a lethal challenge
with FMDV C-S8c1, after vaccination with a single dose of C-S8p260. Pigs immunized with different C-S8p260 doses and
challenged with FMDV C-S8c1 either did not develop any clinical signs or showed delayed and mild disease symptoms. C-
S8p260 induced high titers of both FMDV-specific, neutralizing antibodies and activated FMDV-specific T cells in swine, that
correlated with solid protection against FMDV.
Conclusions: The defective virus-based vaccine did not produce detectable levels of transmissible FMDV. Therefore, a
segmented, replication-competent form of a virus, such as FMDV C-S8p260, can provide the basis of a new generation of
attenuated antiviral vaccines with two safety barriers. The design can be extended to any viral pathogen that encodes trans-
acting gene products, allowing complementation between replication-competent, defective forms.
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Introduction
Application of genetically modified viruses, deficient in replica-
tion, that are incapable of developing a productive infection is a
promising strategy to design safe and effective vaccines. We have
carried out extensive studies on viral population dynamics using an
important pathogen in animal health, foot-and-mouth disease virus
(FMDV). FMDV is an aphthovirus of the Picornaviridae family. Its
genome is a positive strand RNA molecule of about 8,500
nucleotides. It encodes a single polyprotein which is post-
translationally processed by viral proteases into the structural
proteins (VP1–VP4) of the viral capsid, as well as nine different
mature non-structural proteins, and several processing intermedi-
ates, involved in replication functions [1,2,3,4]. Sequential passages
of biological clone FMDV C-S8c1 in BHK-21 cells at high
multiplicity of infection (MOI) resulted in the generation and
dominance of defective RNAs which complemented each other to
produce progeny, and to kill cells in the absence of standard virus
[5,6]. The different defective genomes that were characterized
included a deletion of either 417 nucleotides in the L (leader
protease)-coding region, or of 999 or 1017 nucleotides within the
capsid-coding region. Other deletions were also present at lower
frequencies [6]. Because the deletions of 417 and either 999 or 1017
nucleotides were the most frequent, we refer to two classes of
defective genomes. However, as for any RNA virus, the population
consists of a swarm of non-identical genomes with mutations and
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the same cell, the two classes of defective genomes were efficiently
replicated, and were packaged into separate viral particles [5,6].
Therefore, in following rounds of infection, at least two particles
bearing different deletions had to co-infect the same cell for progeny
virus production [7]. This defective-complementing virus system
was termed C-S8p260. The limitation of C-S8p260 to spread upon
dilution should offer a safety barrier against transmission of
infectious virus following an initial replication in vivo.
FMD is one of the most economically devastating diseases of
cloven-hooved animals, that results in great reduction of
productivity in adult farm animals, high mortality among young
animals, and severe restrictions in the trade of animals and their
products [8,9,10,11]. The threat posed by FMDV is due to a
combination of virological characteristics such as high contagious-
ness, virion stability in the environment (including survival in
infected carcasses), a rapid replication cycle, short incubation
times, and high level of virus excretion via aerosols. Other features
that contribute to the difficulties encountered to combat the
disease are high mutation rates and the quasispecies nature of viral
populations, that lead to antigenic variation, reflected in the seven
serotypes and the numerous antigenic variants described to date
(reviewed in [12,13]). Antigenic diversity and heterogeneity of
FMDV require the periodic updating of multivalent vaccine
formulations to match the antigenic specificity of the vaccine with
that of the viruses circulating in the field. FMDV is a global
problem since it is endemic in parts of Asia, Africa, the Middle
East and South America, with sporadic outbreaks in other areas
considered free of the disease such as Europe and Japan.
Therefore, controlling both endemic and epidemic FMD has
become a global aim.
Currently, vaccination and culling of infected animals and
their contacts are the major means to control FMD [3].
Vaccination in endemic areas is implemented mainly by periodic
administration of a vaccine based on chemically inactivated virus
[14,15]. Despite extensive research to develop a synthetic vaccine
against FMD, no peptide- or protein subunit-based anti-FMD
vaccines have been licensed. Virus immunization with conven-
tional vaccines usually elicits high levels of circulating neutralizing
antibodies, which, together with a T-cell response, correlate with
protection against homologous and antigenically closely related
FMDVs [16,17,18,19].
In the present report we evaluate the immunogenicity of C-
S8p260 and its capacity to confer protection against challenge
with FMDV C-S8c1 using an adult mouse model [20] and swine,
the natural host of the parental, virulent FMDV C-S8c1.
Specifically, all experiments are being carried out with a mixture
of virus variants (collectively called C-S8p260) all of which are
harbouring defective genomes (deletions of 417 and either 999 or
1017 nucleotides) that individually are not infectious but by
complementation will yield plaque upon co-infection. The
rationale for this design was to enhance the effectiveness of
presentation of viral antigenic sites, through transient replication
of the defective ensemble, capable of stimulating a response to B-
and T-cell epitopes. We show that indeed the defective virus
population is able of eliciting a cellular and humoral immune
response, but not of developing viremia, or being transmitted
from vaccinated to contact animals. Thus, we propose a new
design of an attenuated vaccine consisting of complementing,
defective genomes, thereby incorporating safety features of an
inactivated vaccine. The design can be applied to other viral
pathogens whose replication tolerates internal deletions of
genomic regions whose expression products can be complemented
in trans.
Results
Immunization with C-S8p260 confers protection against
FMDV in mice
Adult C57BL/6 mice are a valid surrogate model for FMDV
infections, with features of pathogenesis shared with natural hosts
of FMDV [20,21]. Previous studies indicated that subcutaneous
inoculation at 10
3 PFUs of C-S8c1 in the footpad (FP) of adult
C57BL/6 mice resulted in 100% mortality within 2–3 days [20].
Thus, we used C57BL/6 mice as an animal model to evaluate the
immunogenicity and capacity of the defective genome-based
population C-S8p260 to confer protection against infection with
FMDV C-S8c1. Two groups of sixteen mice were inoculated in
the FP with either 10
3 or 10
7 PFUs of C-S8p260 (see Materials
and Methods for specific determination of C-S8p260 titer); four
animals were inoculated with PBS, as control. Each mouse was
bled at days 1, 2, 3, 15, 30 and 90 post-inoculation (pi) to
determine levels of virus antigen, and antibody titers elicited by C-
S8p260. No virus was detected in blood samples at any time pi
with either dose of C-S8p260 by plaque assay in BHK cells and
FMDV RNA quantification as described in Materials and
Methods. In addition, FMDV RNA was not detected in several
tissue samples (heart, pancreas, spleen, liver, lung and kidney) from
C-S8p260 inoculated mice at 48 hours pi by FMDV RNA
quantification (data not shown). The animals showed no signs of
disease, indicating that the mixture of C-S8p260 genotypes is
highly attenuated for adult C57BL/6 mice. At day 90 pi, mice
were challenged with 10
4 PFUs of FMDV C-S8c1 (ten times the
lethal dose [20]), and viremia and survival rates were examined.
All the unvaccinated control animals died at day 2 post-challenge
(pc), as expected [20]. In contrast, none of the mice vaccinated
with C-S8p260 died or developed any symptom associated with
FMDV replication (Figure 1A). FMDV-specific IgG levels
increased following immunization (Figure 1B). More interesting,
significant neutralizing antibody titers were measured in sera from
all mice just before challenge, and the titers did not increase
following the challenge with FMDV C-S8c1, except for animals #
7, 22 and 27 that had low antibody titers prior to challenge
(Table 1). No significant differences in total IgG or in neutralizing
antibody titers were found between mice inoculated with
10
3 PFUs or 10
7 PFUs of C-S8p260. These data indicate that
mice immunized with C-S8p260 were able to elicit an immune
response against FMDV which was potent enough to confer
protection.
To investigate whether C-S8p260 could be used also as an
inactivated vaccine, we have used binary ethylenimine (BEI)
inactivation as an effective method to achieve the irreversible loss
of viral infectivity with minimal loss of antigenic properties
[22,23,24]. ELISA test against a panel of monoclonal antibodies
specific for the main FMDV antigenic site (site A) have shown no
differences in antigen recognition between C-S8p260-BEI-inacti-
vated virus and C-S8p260 (data not shown). Mice were inoculated
intramuscularly with BEI-inactivated C-S8p260 (equivalent to
5610
6 PFUs, see Materials and Methods for the correction
between measured PFUs and number of infectious particles),
and received a booster with identical dose and composition at day
15 post-immunization. At 15 days post-booster the animals were
challenged with 10
4 PFUs of C-S8c1 in the FP. Following
challenge, immunized mice showed no clinical signs or death
associated with FMDV replication, including viremia, while
control, non-immunized mice died by day 2, as expected [21]
(data not shown). High titers of FMDV-specific IgGs were
determined before challenge, and titers did not increase
significantly after challenge (Figure 1C). These data suggest that
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specific immune response able to protect mice against a lethal dose
of FMDV C-S8c1.
One main concern is the possibility that reconstruction of
standard virus by recombination between two defective genomes
would generate a competent virus able to replicate and cause
disease. To determine the virulenceof the standard virus population
(C-S8p260p3d), rescued by recombination between the two
defective forms [5,6], 21 mice were inoculated with 10
7 PFUs of
C-S8p260p3d in the FP, the maximal dose that can be obtained
with C-S8p260p3d. None of the mice inoculated with C-
S8p260p3d died or developed any clinical symptom associated to
FMDV replication (Fig. 1D). Thus, the replication-competent virus
C-S8p260p3d is highly attenuated for mice (see also Discussion).
Pigs immunized with C-S8p260 were protected against
FMDV C-S8c1 challenge
The effectiveness of C-S8p260 as a potent FMD vaccine in mice
prompted us to investigate the efficacy of C-S8p260 as a vaccine in
pigs, one of the natural hosts of FMDV, and the host from which
FMDV C-S8c1 was isolated [25]. To evaluate C-S8p260 as a
vaccine in swine, four different vaccination regimes were used
(Table 2). In group 1, six pigs (pigs numbered 1 to 6) were
vaccinated with 5610
6 PFUs of C-S8p260 with incomplete
Freund’s adjuvant, and boosted 15 days post-immunization with
the same dose and composition of antigen. In group 2, three pigs
(numbers 7 to 9) were vaccinated with 10
3 PFUs of C-S8p260 with
adjuvant, and boosted 15 days post-immunization with the same
dose and composition of antigen. In group 3, two pigs (numbers 10
and 11) were vaccinated with 5610
6 PFUs of C-S8p260 without
adjuvant, and boosted 15 days post-immunization with the same
amount of antigen, without adjuvant. In group 4, three pigs
(numbers 12 to 14) were vaccinated with BEI-inactivated C-
S8p260 with adjuvant, and boosted with the same dose and
composition of antigen at 15 days post-immunization. Finally, in
group 5, 3 pigs (numbers 15 to 17) were administered PBS, and
served as negative controls. All groups were challenged at 18 days
post-booster (33 days post-immunization) with 10
5 PFUs of
FMDV C-S8c1, and clinical signs were scored for 12 days, as
described in Materials and Methods.
Figure 1. Immunogenicity of C-S8p260 in mice. C57BL/6 mice were inoculated in the FP with either 10
3 or 10
7 PFUs of C-S8p260, or
PBS. At 90 days post-immunization, mice were challenged with 10
4 PFUs of FMDV C-S8c1 (procedures are described in Materials and Methods). A.
Survival curves after immunization and after challenge (indicated in the abscissa, with arrow in the bottom panel). Continuous line: animals
immunized with C-S8p260; discontinuous line: animals inoculated with PBS. B. IgG titers determined by ELISA at different days post-immunization
and after challenge (abscissa and bottom panel). C. IgG titers in serum of mice immunized with BEI-inactivated C-S8p260. The day of the challenge
with 10
4 PFUs of C-S8c1 is indicated with an arrow; 16 animals were inoculated in each group. D. Survival of mice inoculated with C-S8p260p3d and
C-S8c1; 21 mice were inoculated with 10
7 PFUs C-S8p260p3d (squares), and 10 mice with 10
3 PFUs of C-S8c1 (diamonds).
doi:10.1371/journal.pone.0010414.g001
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of disease by 2 days pc, and had a significant lesion score (Table 2).
In contrast, the animals to which C-S8p260 was administered
(groups 1, 2 and 3) never developed any clinical signs of disease.
Two out of three animals in group 4 (pigs 12 and 13) vaccinated
with BEI-inactivated C-S8p260 showed delay in the onset of
clinical symptoms, with a low score (5), while pig 14 did not show
any clinical symptom. Comparison of the results of groups 1, 2 and
3 suggest that transient replication of C-S8p260 in swine
contributed to increase the level of protection (see Discussion).
Viremia was evaluated in all the animals by determination of
infectivity (PFUs/ml) and FMDV RNA level in serum (Table 2).
The control group (group 5) developed viremia at day 1 pc, lasted
for 5–6 days, and reached an average peak value of 1610
5 PFUs/
ml of serum. The animals in groups 1 and 2 did not develop
viremia detected by infectivity (,10 PFU/ml serum). However,
the serum of animal 6 in group 1 was positive for FMDV RNA
(10
5 RNA molecules/ml of serum), despite no detectable
infectivity. The RNA levels were 10
4-fold lower than in the
control group (1–7610
9 RNA molecules/ml serum). All the
animals in group 3 and 4 developed viremia detected by real time
RT-PCR, but the onset of viremia was delayed, viremia lasted for
a shorter period of time, and the number of FMDV RNA
molecules was generally 10
3-t o1 0
4-fold lower than in the control
animals. One exception was animal 14 (group 4) that did not
develop any viremia or clinical symptom. Viral RNA was also
detected in the nasal swabs of the control group and in animals of
group 4, although the duration of positive FMDV RNA was
shorter than in the control group. No virus was detected in the
nasal swabs of protected animals. These results indicate that
immunization of pigs with C-S8p260 plus adjuvant conferred solid
protection against FMDV C-S8c1 challenge, and limited the
replication of FMDV in the challenged animals, that did not
contain detectable viral RNA in their nasal secretions.
C-S8p260 induces systemic FMDV-specific antibodies and
high titers of neutralizing antibodies
FMDV-specific antibody responses were quantitated by ELISA
in serum of pigs inoculated with C-S8p260. IgG levels systemat-
ically rose from those scored at 2 days post-challenge (dpc) to those
scored at 7 dpc (Figure 2). The only animal that did not develop
any FMDV-specific antibody was number 12 of group 4, and this
animal was not protected against FMDV challenge (Table 2).
IgG1 levels were only slightly higher than IgG2 responses.
Exceptions were animals 1 and 10 of groups 1 and 3, respectively.
Animal 1 did not develop any detectable IgG2 at any time, and
animal 10 did not produce IgG2 until 7 days pc. Vaccination also
resulted in a rapid IgM response. In most of the animals (except
numbers 2, 3 and 7), there was an increase of the IgM responses by
day 7 pc.
FMDV-specific neutralizing antibodies were found in sera from
all pigs after vaccination, except in pig number 12 (Table 3). All
animals in group 1, and animals 7, 13 and 14 showed significant
neutralization titers (value of PRN70.1.2) after the first vaccine
administration. After booster vaccination, titers increased in all
animals, even in those that did not display significant neutraliza-
tion titer after administration of the first dose. Neutralization titers
increased slightly at 2 and 7 days pc.
The effect of vaccination in systemic IgA responses was also
evaluated due to their role in mucosal immunity and their
relevance for protection against FMDV [26,27]. Animals in group
1 and 3 showed a strong induction of IgA early after vaccination
with the exception of animal 2 (Figure 3). No IgA induction was
observed in other groups. This suggests that a high dose of C-
S8p260 might be required to induce a specific IgA response that
may contribute to FMDV mucosal immunity. Taken all these data
together, we conclude that the vaccine formulation based on
replication-competent defective FMDV genomes is able to evoke a
FMDV-specific humoral immune response in swine.
C-S8p260 induces a FMDV-specific T cell response
To evaluate the induction of FMDV-specific T cells as a result
of vaccination, lymphoproliferation assays were carried out with
PBMCs of vaccinated pigs. The stimulation indexes (SI) of PBMCs
at day 30 post-vaccination (pre-challenge) and day 11 post-
challenge were compared (Figure 4A). Highly specific responses
(SI.6) were detected in all groups, except in animal 12 of group 4.
Proliferative responses were also detected after challenge, with
high values of SI for animals 2, 3, 4, 8, 9, 11 and 14. By contrast,
animals 1, 5, 6, 7, 10 and 13 did not show any significant increase
in the SI after challenge, with animals 5 and 10 showing lower
values of SI after challenge than before challenge. The control
group (group 5) showed a significant SI at day 11 pc. In addition,
we have determined the production of IFN-c in supernatants of
PBMCs from vaccinated pigs at day 30 post-vaccination (pre-
challenge) and day 11 pc. In both cases, the IFN-c levels correlated
Table 1. Neutralizing antibody response against FMDV C-
S8c1, in mice, after vaccination with C-S8p260.
C-S8p260
a Neutralization titer (PRN70)
b
10
7 PFUs 30 days PI
c 3 days PC
d
Mouse #
1 2.0 1.8
2 2.0 2.0
3 2.4 2.2
4 2.1 1.9
5 1.3 1.5
6 1.7 1.8
7 0.4 1.9
8 1.7 1.8
9 2.7 2.4
10 1.9 1.9
10
3 PFUs
Mouse #
20 2.0 1.9
21 2.1 1.8
22 ,01 . 8
23 1.7 1.8
24 1.4 2.4
25 1.6 1.8
26 1.4 1.8
27 0.6 1.1
28 1.4 1.5
29 1.7 1.8
aMice were vaccinated with 10
7 PFUs or 10
3 PFUs of C-S8p260, indicated for
each group.
bNeutralization titers are expressed as PRN70 (plaque-reduction neutralization
titer 70): the reciprocal of the dilution of serum that causes neutralization of
70% of PFU.
c30 days post-immunization.
d3 days post-challenge with 10
4 PFUs of C-S8c1.
doi:10.1371/journal.pone.0010414.t001
Defective Genomes as Vaccine
PLoS ONE | www.plosone.org 4 April 2010 | Volume 5 | Issue 4 | e10414with the lymphoproliferative responses (Figure 4B). This pattern of
cytokine production and the lymphoproliferative responses
indicates that immunization with C-S8p260 primes T cells that
can recognize the viral epitopes presented in the context of a
subsequent viral encounter. Thus, a vaccine consisting of defective,
complementing versions of the FMDV genome can evoke both an
antibody and a cellular immune response, which results in
protection of swine when challenged with the corresponding
virulent FMDV.
Discussion
The work presented here reports a potential use as vaccine of
unique viral particles that we discovered upon extensive passage of
FMDV in BHK-21 cells [5]. We show that defective genomes that
can replicate in the absence of wild type virus confer full protection
in mice and pigs against FMDV challenge. Such a bipartite
particle system (with two classes of genomes with internal
deletions, but consisting of a mutant spectrum, with multiple
minority genomes with non-identical internal deletions [6]) can be
regarded as a candidate anti-FMD vaccine. Its key features are
that the initial virus replication in the animal would mimic a true
live-attenuated virus, and that subsequent rounds of infection
would be limited by the requirement of co-infection of the cells by
two different classes of viral particles. The results cannot exclude
that at the site of inoculation a full length recombinant genome
could be generated, and that its transient replication could
contribute to the observed immune response. However, if
reconstruction of standard virus by recombination occurred in
the vaccinated animals, it would generate a replication-competent
but highly attenuated FMDV recombinant (Figure 1D), a result
expected from previous results of attenuation for mice and cattle of
FMDV passaged in cell culture [28,29] (Rodrı ´guez-Calvo and
Sevilla, unpublished results). Thus, it is highly unlikely that a
recombinant standard virus could arise in the animals and acquire
the mutations needed for virulence. This is because the segmented
form has manifested a selective advantage relative to the
corresponding standard virus generated by recombination (48;
Ojosnegros et al., manuscript in preparation). Since generation of
the recombinant necessitates co-infection of the same cell by the
two types of defective genomes it is unlikely that the recombinant
would gain in the competition. Under these conditions it seems
unlikely that the recombinant, standard genome, would undergo
sufficient rounds of replication to acquire the virulence-associated
mutations. In fact such acquisition would be less likely than upon
administration of the standard genome alone. As documented in
Results, no virulent variants were detected upon administration of
the standard, recombinant-derivative genome in isolation.
Classic whole-virus inactivated vaccines against FMD have been
successful in controlling the disease, but have met with the
problem of outbreaks associated either with incomplete inactiva-
tion of the virus during vaccine manufacturing or with escape of
virus from vaccine production factories [30]. The development of
new, safe and effective vaccines to control FMD must take into
consideration the problem of the extensive antigenic heterogeneity
of natural FMDV populations, including antigenic differences
Table 2. Clinical manifestation in swine inoculated with C-S8p260 and challenged with FMDV C-S8c1.
Group
Inoculum(PFUs of
C-S8p260) Animal
Viremia (dpc, day of onset,
duration in days)
a
Nasal swab specimen (dpc,
day of onset, duration [days])
b
No. of lesions
(day of onset)
c
15 610
6+Adj 1 Neg. Neg. Neg.
2 Neg. Neg. Neg.
3 Neg. Neg. Neg.
4 Neg. Neg. Neg.
5 Neg. Neg. Neg.
6 2.5610
5 (4, 4, 1) [Neg.] Neg. Neg.
21 0
5+Adj 7 Neg. Neg. Neg.
8 Neg. Neg. Neg.
9 Neg. Neg. Neg.
35 610
6 10 2.5610
5 (2, 2, 2) [Neg.] Neg Neg
11 3.1610
5 (2, 2, 2) [Neg.] Neg Neg
4 BEI inactivated 12 7610
5 (2, 2, 4) [1.2610
4]2 . 8 610
5 (4, 4, 1) 5 (3)
13 2610
5 (2, 2, 4) [1610
4]3 . 7 610
6 (4, 4, 1) 5 (4)
14 Neg. Neg. Neg.
5 Non vaccinated 15 6.2610
9 (3, 1, 5) [1610
5]2 610
8 (4, 2, 2) 15 (2)
16 7610
9 (3, 1, 5) [1.1610
5]1 . 2 610
7 (4, 3, 2) 16 (2)
17 1.1610
9 (3, 1, 6) [6.5610
4]1 . 1 610
6 (4, 3, 2) 11 (2)
aViremia is expressed as FMDV RNA molecules/ml of serum quantified by
qRT-PCR (Neg. means,10
3 FMDV RNA molecules/ml of serum). The three numbers given in
parenthesis correspond to: dpc, the day after challenge at which the maximum level of viremia was detected; the first dpc at which viremia was detected; and the third
value is the number of days of duration of viremia. The infectivity of those sera that were positive for FMDV RNA is indicated in brackets as PFU/ml of serum; [Neg.]
means,100 PFU/ml of serum.
bFMDV RNA molecules per ml of nasal secretion (Neg. means,10
3 FMDV RNA molecules per ml of nasal secretion). The dpc, onset, and duration values are as defined in
footnote a.
cNumber of toes with lesions plus the snout and tongue combined, when lesions were present. The maximum score is 17. The day of onset (given in parenthesis) is the
first day after challenge at which lesions were detected.
doi:10.1371/journal.pone.0010414.t002
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heterogeneity is a consequence of high mutation rates and
quasispecies dynamics, and it is common to most pathogenic
RNA viruses (reviewed in [34]). For a vaccine to be effective to
control highly variable RNA viruses, it must evoke a broad
immune response targeted to many independent T-cell and B-cell
epitopes, in order to prevent selection of vaccine-escape mutants.
Despite a broad immune response, the vaccine is unlikely to confer
protection against infection by viruses of a different serotype, and
multivalent vaccines are required. Such a broad immune response
can, in principle, be best accomplished with live-attenuated virus
vaccines, and it is unlikely to be achieved with individual surface
proteins expressed in heterologous vector systems, or with
synthetic peptides that represent a restricted number of epitopes.
These limitations have been amply manifested in previous
unsuccessful attempts to produce a synthetic vaccine against
FMD [35,36,37,38,39].
Live-attenuated viral vaccines that replicate in the host without
producing disease expose the host to a greater antigenic mass and
diversity of epitopes than the corresponding whole-virus inacti-
vated vaccine. In addition, if delivered by the natural route,
attenuated vaccines can induce mucosal immunity [40]. Howev-
er, this basic principle of vaccinology is not easy to put into
practice for several reasons. One is that, because of the error-
prone replication of RNA viruses, attenuated virus variants can
revert to virulent forms, as extensively documented for live
poliovirus vaccines [41,42,43]. While attenuated anti-FMD
vaccines were used in some countries [10,44], they were replaced
by chemically inactivated whole virus antigen used in conjunction
with an adjuvant, for safety considerations. Nevertheless, new
promising versions of live-attenuated anti-FMDV vaccines have
been developed. Thus, genetically engineered FMDV serotype
A12 lacking the coding region for the L proteinase induces a
partial protective immune response in cattle and swine against
FMDV challenge [45,46]. However, attenuated vaccines engi-
neered to have a large genetic barrier to reversion may produce
too weak an immune response (excess attenuation), resulting in
low effectiveness.
These multiple problems led us to investigate the use of C-
S8p260, a bipartite FMDV version of infectious particles, as a
potential FMDV vaccine. The original passage experiments of
FMDV C-S8c1 in BHK-21 cells were undertaken to determine a
possible limit for fitness gain of a virus replicating in a constant
biological environment, one of the open questions in viral
population dynamics [47]. Unexpectedly, the virus evolved towards
genomic forms with internal deletions that were packaged into
separate particles and that required complementation to produce
infectious progeny and kill cells [5,7]. Both live C-S8p260 and BEI-
Figure 2. Serum IgG1, IgG2 and IgM-specific responses in pigs following immunization with C-S8p260. Each column corresponds to the
antibody titer for the indicated animal (numbers 1 to 14) at different times (D, day) post-immunization and post-challenge (white bars: D15 pi; light
gray: D30 pi; dark grey: D32 pi (that corresponds to D2 post-challenge), and black: D37 pi (that corresponds to D7 post-challenge). Titers are
expressed as the reciprocal of the highest dilution of serum (log10) that gives an ODA460 of twice the value obtained with the pre-immune serum of
the corresponding animal.
doi:10.1371/journal.pone.0010414.g002
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sterile protection of swine required live C-S8p260 (Table 2). This
suggests a role of viral replication in the induction of a protective
response. Since viremia was absent in mice and swine vaccinated
with C-S8p260, replication of C-S8p260 (or a possible recombinant
with a full length genome) must have been transient and probably
limited to the inoculation site and surrounding tissues. Absence of
viremia is consistent with the requirement of C-S8p260 progeny to
co-infect cells to sustain the infection. Dilution of progeny particles
(into surrounding tissues, blood) should effectively interrupt the
Table 3. Neutralizing antibody response to FMDV C-S8c1 in sera of pigs vaccinated with C-S8p260.
Animals Virus neutralization titers (VNT)
a at the indicated day after immunization
0 15 30 32 (D2 pc)
b 39 (D7 pc)
c
Group #1
1 ,0 1.2 1.8 2.5 3.7
2 ,0 1.3 1.5 3.0 3.6
3 ,0 2.2 3.4 3.4 3.5
4 ,0 1.9 2.5 2.5 3.3
5 ,0 1.5 2.3 2.3 3.4
6 ,0 1.3 2.8 2.7 2.7
Group #2
7 ,0 2.4 2.3 2.5 2.8
8 ,0 ,0 1.8 2.3 3.0
9 ,0 ,0 2.2 2.5 3.0
Group #3
10 ,0 ,0 1.8 1.8 2.7
11 ,0 ,0 1.4 1.3 3.0
Group #4
12 ,0 ,0 ,0 1.7 1.7
13 ,0 0.4 2.0 2.0 3.1
14 ,0 2.5 2.5 2.6 3.2
Group #5
15 ,0 ,0 ,0 ,02 . 3
d
16 ,0 ,0 ,0 ,03 . 1
d
17 ,0 ,0 ,0 ,02 . 2
d
aVNT, virus neutralization titer (log10 of the reciprocal of the last dilution able to neutralize 70% of 100 PFUs of FMDV C-S8c1).
bDay 2 post-challenge with 10
5 PFUs of FMDV C-S8c1.
cDay 7 post-challenge with 10
5 PFUs of FMDV C-S8c1.
dFor control animals, VNT was obtained at day 12 pc.
doi:10.1371/journal.pone.0010414.t003
Figure 3. Serum IgA-specific responses in pigs following immunization with C-S8p260. Each column corresponds to the antibody titer for
the indicated animal (numbers 1 to 14) at different times (D, days) post-immunization and post-challenge (white bars: D15 pi; light gray: D30 pi; dark
grey: D32 pi (that corresponds to D2 post-challenge), and black: D37 pi (that corresponds to D7 post-challenge). Titers are expressed as the reciprocal
of the highest dilution of serum (log10) that gives an ODA460 of twice the value obtained with the pre-immune serum of the corresponding animal.
doi:10.1371/journal.pone.0010414.g003
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benefits of a vaccine based on C-S8p260 over the corresponding
BEI-inactivated vaccine were not due to a transient replication of
the live C-S8p260 but to loss of epitopes as a result of the BEI
inactivation. Although it cannot be excluded that some epitopes
might be lost as a result of treatment of C-Sp260 with BEI, previous
investigations as vaccine preparation and efficacy led to the choice
of BEI as an adequate reagent to inactivate FMDV while
maintaining its immunogenic properties [23]. Furthermore, we
have compared the antigenic properties of C-S8p260 and C-
S8p260-BEI-inactivated and did not show any difference (data not
shown). Concerning an initial replication of C-S8p260, it would be
technically very difficult to prove or disprove its occurrence. At least
from our experimentally observations in cell culture [5,6,48] and
theoretical studies on bipartite virus dispersal [7] it is extremely
unlikely that the cell adjacent to the inoculation site would not be
dually infected by the two particle components of C-S8p260. Yet, it
is not possibleto anticipatehowmany roundsof multiplicationof C-
S8p260 will be established in cells progressively distant from the
inoculation site because finally viral dilution will stop progress of the
infection [7], as evidence by the absence of viremia. Independently
of the number of rounds of progeny production, a vaccine based on
two-component viral preparation will have a safety barrier
additional to mere attenuation of a standard one-component virus,
and immunogenicity may still be maintained upon chemical
inactivation.
The solid protection observed by C-S8p260 correlated with the
detection of high levels of circulating neutralizing FMDV
antibodies. Interestingly, FMDV-specific IgA antibodies were
detected mainly in animals from group 1 and 3, those vaccinated
withthe highest antigen dose (5610
6 PFUs of C-S8p260) (Figure 3).
The induction of IgA response upon vaccination with C-S8p260,
and its possible role in protection against challenge with FMDV,
merits further investigation. Vaccination with C-S8p260 also
elicited T cells that consistently proliferated when stimulated with
FMDV (Figure 4). After FMDV challenge, proliferation was
maintained or increased, suggesting that C-S8p260 primes T cells
that can recognize the viral epitopes presented in the context of a
subsequent virus encounter. Altogether, our results suggest that
vaccination with C-S8p260 induces T- and B-cell activation that
efficiently contributes toFMDV protection. Obviously,protectionis
not expected to extend to other FMDVs of a different serotype.
Additional work is needed to investigate the response of vaccinated
animals upon challenge with heterologous virus, in particular other
FMDV subtypes within type C, and also to establish the duration of
protection against challenge with homologous virus.
Thus, we arrive at a vaccine based on defective FMDV
genomes that recapitulates features of an attenuated (due to the
initial viral replication) and of an inactivated (due to low
probability of double infections as the virus spreads in the animal)
vaccine. The vaccine could be easily marked by a tagged antigen
inserted in-frame in the place of the deletion of the defective
Figure 4. FMDV-specific T cell responses in vaccinated pigs. PBMCs were purified from blood of animals at day 30 (D30) post-immunization
(pre-challenge) (white bars), and D11 post-challenge (grey bars). A. Lymphoproliferative responses of pigs 1 to 17 (groups 1, 2, 3, 4 and 5) to FMDV C-
S8c1. Data are shown as stimulation index (see Material and Methods) and standard deviations are indicated. B. IFN-c release by PBMC stimulated
with FMDV C-S8c1. Values were determined at 72 h of in vitro stimulation. The detection level in control cultures (medium alone) were below the
sensitivity of the assay (5 pg/ml).
doi:10.1371/journal.pone.0010414.g004
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animals [15]. The new vaccine design encompasses at least two
safety levels that apply both to vaccine manufacture and to vaccine
administration to animals. The first safety level resides in genome
segmentation. Infection (in the vaccinated animals or in the event
of virus escape from a production unit) will be self-limiting, as
documented by absence of viremia and virus in nasal secretions
upon vaccination of swine with C-S8p260. Second, if standard
virus is reconstructed from the defective virus, its attenuation
together with the evoked immune response, will render disease by
such recombinant extremely unlikely. Additionally, as argued in
more detail earlier, since defective FMDV particles interfere with
replication of the standard virus in cell culture [48], a dominance
of the segmented defective FMDV virus over a possible standard
virus generated by recombination is expected, and renders very
unlikely and reversion of standard virus to a virulent form. Finally,
the results reported in our study suggest that higher doses of BEI-
inactivated C-S8p260 are also likely to confer protection. If
substantiated, this would provide the vaccine with an additional,
third safety barrier because it would consist of an inactivated
vaccine (as those currently in use [49]) devoid of any potential
danger in the event of incomplete inactivation. Experiments to test
these possibilities are in progress.
The proposed vaccine could be administered together with
interferon, or other immunostimulatory molecules, to evoke short-
term protection, as documented for other anti-FMD vaccines
[50,51]. Genomes with internal deletions of the type present in C-
S8p260 should not be difficult to construct with other FMDV
serotypes, given the similarity in replication cycles of all FMDVs,
and the availability of FMDV replicons lacking substantial
portions of the genome [52]. Also, the new vaccine design should
be applicable to other RNA viruses, since virus versions with
additional genomic segments have been engineered for measles
virus [53,54,55,56] and for lymphocytic choriomeningitis virus
[57]. The genetic flexibility of RNA viruses may be exploited to
engineer vaccine strains that combine features of an attenuated
and of an inactivated vaccine, to procure an effective protection.
Materials and Methods
Ethics Statement
All the experiments involving animals were approved by the
ethical review committee at the Centro de Investigacio ´n en
Sanidad Animal (CISA-INIA), following guidelines set forth the
European Union (Directive 86/609/EEC).
Virus
FMDV C-S8c1 is a plaque-purified virus of the European
serotype C, natural isolate C1 Santa-Pau Spain 70 [25]. FMDV C-
S8p260 is a viral population obtained after 260 serial cytolytic
passages of C-S8c1 at high multiplicity of infection in BHK-21
cells, and C-S8p260p3d is a viral population obtained after 3 serial
cytolytic passages of C-S8p260 at low multiplicity of infection in
BHK-21 cells [5]. The titers given for C-S8p260 through the text
are corrected infectivity. Since a PFU requires co-infection of a cell
by at least one of each type of particles harbouring different
internal deletions in the RNA [5,6,25,48], a correction is needed
to convert the observed PFUs into number of infectious particles
(n). This correction can be done by applying the formula: n=!4N
(PFU), in which N is the total number of cells [7].
Immunization and experimental infections
C57BL/6 female mice (7–8 weeks old) were used for mice
experiments. Mice were given a single dose subcutaneously in the
footpad (FP) of 10
7 or 10
3 PFUs of C-S8p260. After 90 days post-
immunization, mice were challenged with 10
4 PFUs of C-S8c1 in
the FP. For the experiments with swine, 17 domestic Landrace X
Large White pigs, 2 months old (approximately 30 to 40 Kg) were
divided into five groups: group 1 included 6 pigs that were
immunized with 5610
6 PFUs of C-S8p260 with incomplete
Freud’s adjuvant, with a booster immunization 15 days later;
group 2 included 3 pigs that were immunized with 10
5 PFUs of C-
S8p260 with incomplete Freud’s adjuvant, with a booster
immunization 15 days later; group 3 included 2 pigs that were
immunized with 5610
6 PFUs of C-S8p260 without adjuvant, with
a booster immunization 15 days later; group 4 included 3 pigs that
were immunized with BEI-inactivated FMDV C-S8p260 (equiv-
alent to 5610
6 PFUs) with incomplete Freud’s adjuvant, with a
booster immunization 15 days later; and group 5 included 3 non-
vaccinated pigs as controls. Animals were immunized via
intramuscular injection. All animals were challenged at day 30
post-immunization by injection of 10
5 PFUs of FMDV C-S8c1 in
the coronary band of the left rear foot. This route of challenge in
swine is one recommended by the OIE. The animals were
monitored for 12 days after challenge. Rectal temperatures, lesion
data, and the physical conditions of the animals were determined
daily. Blood and nasal swab specimens were collected daily for the
first 7 days after challenge, and serum samples were collected
every other day. Lesion scores of the animals were determined by
evaluating the number of digits with lesions and adding the snout
and tongue combined, if vesicles were present (maximum score,
17). The animal experiment was performed in the secure disease
agent isolation facilities at the Centro de Investigacio ´n en Sanidad
Animal (CISA-INIA) according to a protocol approved by the
Institutional Animal Care and Use Committee.
Detection of isotype-specific FMDV-antibodies by ELISA
ELISA was used to measure isotype-specific FMDV-antibodies
as previously described [58]. Briefly, 96 wells polyvinylchloride
(PVC) microplates (Flow Laboratories) were coated at 4uC
overnight with rabbit anti-FMDV serotype C. The antigen
(FMDV C-S8c1) was added and incubated for 1 hour. Then,
sera from mice or pigs were diluted into PBS/3% ovalbumin and
analyzed for the presence of isotype-specific antibodies. Monoclo-
nal antibodies specific for swine IgG1, IgG2, IgM and IgA were
supplied by Serotec, and mouse IgG by BioRad. Antibody titers
were expressed as the reciprocal of the highest dilution giving an
ODA460 of twice the value obtained with pre-immune serum for
each animal.
Seroneutralization assay
Neutralization of infectivity by swine or mice sera was carried
out by plaque-reduction neutralization assay as previously
described [59]. Briefly, FMDV C-S8c1 (100 to 200 PFUs) was
incubated with serial dilutions of serum for 1 hour at 25uC, at RT.
Then the mixtures were plated on BHK-21 cell monolayers, and
plaques visualized by crystal violet staining. Neutralization titers
are expressed as the reciprocal of the serum dilution that causes
neutralization of 70% of PFUs (PRN70).
Lymphoproliferation assay
Proliferation assays were carried out in 96-well flat-bottomed
microtitre plates. Cells were plated at a concentration of 4610
6/
ml, 100 ml/well in RPMI/10% (v/v) fetal bovine serum, and
0.05 mM 2-mercaptoethanol. Triplicate cultures were stimulated
with 3610
6 PFUs of FMDV C-S8c1. Positive controls of the assay
were stimulated with Concanavalin A (Con A) (Sigma, St. Louis,
MO) at a final concentration of 1 mg/ml. The cultures were
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PLoS ONE | www.plosone.org 9 April 2010 | Volume 5 | Issue 4 | e10414incubated for 3 days at 37uC, 5% (v/v) CO2. They were then
pulsed overnight with
3H thymidine (Amersham, Pharmacia)
(0.5 mCi/well). The cells were harvested onto filter mats using a
cell harvester, and the incorporation of radioactivity into DNA
was measured by liquid scintillation in a Microbeta counter
(Pharmacia, Uppsala, Sweden). Data are expressed as stimulation
index (SI), calculated by dividing the mean cpm obtained in the
stimulated cultures by the mean cpm obtained in the control
cultures.
Cytokine detection
PBMC were incubated with 3610
6 PFUs of FMDV C-S8c1,
and at 72 h post-incubation supernatants were harvested and
analyzed by cytokine production using pig IFN-c ELISA kit
(Bender MedSystems). In each assay, the corresponding cytokine
was diluted over the detection range recommended by the
manufacturer to generate a standard curve from which sample
concentrations (pg/ml) were calculated.
Viral RNA quantification
RNA was extracted from sera or nasal swabs from infected
animals by treatment with Trizol (Invitrogen) according to the
instructions of the manufacturer [60]. FMDV RNA quantification
was performed by real time RT-PCR using the LightCycler
instrument (Roche, Indianapolis, IN, USA) and the RNA Master
SYBR green I kit (Roche), as specified by the manufacturer.
Quantification was relative to a standard curve obtained with
known amounts of FMDV C-S8c1 RNA, using a procedure that
has been previously described [5,61].
Statistical analyses
Data handling, analyses and graphic representation was
performed using Prism 2.01 (GraphPad Software Inc.). Statistic
differences were determined using a Student t test or a one-way
ANOVA (p,0.05).
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